Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Shimena R Li, Terence O'Keeffe, Mazen S. Zenati, Joshua D. Brown, Katherine M. Reitz, Matthew D. Neal, Gary Vercruysse, Bellal Joseph, Raminder Nirula, Francis X. Guyette, Brian S. Zuckerbraun, Brian J. Eastridge, Jason L. Sperry
Publikováno v:
Ann Surg
OBJECTIVE We sought to characterize the timing of administration of prehospital tranexamic acid (TXA) and associated outcome benefits. BACKGROUND TXA has been shown to be safe in the prehospital setting post-injury. METHODS We performed a secondary a
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Amer H. Zureikat, David L Bartlett, Kenneth K. Lee, Mazen S. Zenati, Nathan Bahary, Alessandro Paniccia, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
Ann Surg Oncol
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3263486cc36ea0870e151d9eee750612
https://europepmc.org/articles/PMC8614241/
https://europepmc.org/articles/PMC8614241/
Autor:
Mazen S. Zenati, Herbert J. Zeh, Brian A. Boone, Amr Al-abbas, Melissa E. Hogg, Jillian Bonaroti, Caroline J. Rieser, Amer H. Zureikat
Publikováno v:
HPB (Oxford)
Background The short-term morbidity associated with post-operative pancreatic fistula (POPF) is well established, however data regarding the long-term impact are lacking. We aim to characterize long-term oncologic outcomes of POPF after pancreatic re
Autor:
Nathan Bahary, Caroline J. Rieser, Herbert J. Zeh, Mazen S. Zenati, Kenneth K. Lee, Amer H. Zureikat, Hao Liu, Aatur D. Singhi, Amr Al-abbas, Melissa E. Hogg
Publikováno v:
Ann Surg Oncol
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for f
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Autor:
Mazen S. Zenati, Richard L. Simmons, Jae P. Jung, Amer H. Zureikat, Herbert J. Zeh, Melissa E. Hogg, Ahmad Hamad, Brian A. Boone
Publikováno v:
HPB (Oxford)
Background Achieving margin negative resection is a significant determinant of outcome in pancreatic adenocarcinoma (PDA). However, because of the fibrotic nature of PDA, it can be difficult to discriminate fibrosis from active disease intra-operativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09e641de98a5369e1c6f09dcc4fa25a
https://europepmc.org/articles/PMC6631331/
https://europepmc.org/articles/PMC6631331/
Autor:
Haroon A. Choudry, Matthew P. Holtzman, Steven A. Ahrendt, David L. Bartlett, Heather Jones, Herbert J. Zeh, Joshua Winer, Arun Mavanur, Deepa Magge, Amer H. Zureikat, Kenneth K.W. Lee, Mazen S. Zenati, Lekshmi Ramalingam, James F. Pingpank
Publikováno v:
Annals of Surgical Oncology. 21:1448-1455
Background. Peritoneal carcinomatosis from gastric cancer (GPC) responds poorly to systemic chemotherapy. Limited published data demonstrate improved outcomes after aggressive locoregional therapies. We assessed the efficacy of cytoreductive surgery